A decision from the regulatory agency on approval for SER-109 is anticipated on 26 April next year. Credit: Julia Koblitz / Unsplash.

The US Food and Drug Administration (FDA) has accepted Seres Therapeutics’ Biologics License Application (BLA) for SER-109 to prevent recurrent C. difficile infection (rCDI) for priority review.

A decision from the regulatory agency on approval for the therapy is anticipated on 26 April next year.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Additionally, the FDA said that it is not presently planning to organise an Advisory Committee Meeting to discuss the BLA for SER-109.

The application is based on the findings from concluded Phase III development programme including ECOSPOR III and ECOSPOR IV clinical trials.

The randomised, placebo-controlled, multicentre ECOSPOR III (SERES-012) trial had 182 adult patients with rCDI.

See Also:

According to the trial data, 88% of participants in the SER-109 arm were free from C. difficile recurrence at eight weeks versus 60% in the placebo arm.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The ECOSPOR IV (SERES-013) trial assessed the commercial dose of SER-109 in 263 rCDI patients.

The safety profile of the therapeutic was well-tolerated in the trial, and a sustained clinical response of 91% was reported at eight weeks in the overall group.

An investigational, oral microbiome therapy candidate, SER-109 has purified Firmicutes spores to treat rCDI.

Seres Therapeutics president and CEO Eric Shaff said: “We are working as quickly as possible to bring this first-ever oral microbiome therapeutic to patients most in need if approved.

“The milestone is the result of tremendous hard work and perseverance by our team, and we look forward to collaborating with the FDA through the ongoing review process.”

In July last year, the company and Nestlé Health Science signed an agreement to co-market SER-109 in the US and possibly in Canada.